Ascend Therapeutics

Ascend Therapeutics

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $90M

Overview

Ascend Therapeutics is a private, commercial-stage specialty pharma company concentrating on hormone replacement therapies. Founded in 1999 and headquartered in Herndon, Virginia, it serves as the US subsidiary of Besins Healthcare, a global leader with a long history in hormone science. The company's business model is centered on commercializing Besins' portfolio of approved small-molecule hormone products, primarily in women's health and endocrinology. It is a revenue-generating entity focused on marketing and medical support for its established therapeutic products.

Women's HealthEndocrinology

Technology Platform

Commercialization platform leveraging the inherited hormone therapy expertise, manufacturing, and product portfolio of parent company Besins Healthcare, specializing in natural progesterone and estradiol formulations.

Funding History

2
Total raised:$90M
Series B$65M
Series A$25M

Opportunities

The large and aging demographic seeking menopausal symptom management presents a sustained market.
Growing use of Assisted Reproductive Technology (ART) drives demand for supportive hormone therapies like progesterone.
There is an opportunity to educate the market on the profile of bio-identical hormones and expand appropriate use based on evolving clinical data.

Risk Factors

High competition in the HRT market from generics and large pharma companies.
Ongoing regulatory and safety scrutiny over hormone therapy risks creates market volatility.
Heavy dependency on the parent company for product pipeline and strategic direction limits autonomy.

Competitive Landscape

Ascend operates in the competitive Hormone Replacement Therapy market, competing against large pharmaceutical companies (e.g., Pfizer, Novartis) with major brands, as well as numerous generic manufacturers. Its differentiation lies in its specialized focus on hormones, the legacy of Besins' expertise in natural/bio-identical formulations, and its position as a dedicated subsidiary rather than a division within a large conglomerate.